Abstract
Introduction: Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis and usually attacks the lungs. Indonesia is in the third rank of TB cases in the world. An important concern regarding TB currently is the case of anti-TB drug resistance, hence research on resistance patterns and risk factors is essential. This study aimed to identify the pattern of first-line anti-TB drug resistance at Dr. Soetomo General Hospital, Surabaya.Methods: A descriptive retrospective study was conducted at Dr. Soetomo General Hospital, Surabaya for the period of 2017-2019. The samples were obtained through total population sampling of 239 pulmonary TB patients with first-line anti-TB drug resistance which were registered at MDR-TB Polyclinic Dr. Soetomo General Hospital, Surabaya. Only complete medical records were included. The variables were first-line anti-TB drug resistance (isoniazid, rifampicin, ethambutol, streptomycin) and patients’ characteristics (age, gender, treatment history, and comorbidities). The drug resistance test was performed using certified culture methods.Results: Among 239 patients, the incidences of resistance to H, R, E, and S were 79.08%, 94.14%, 25.94%, and 20.08%, respectively. The most common patterns were HR (42.26%), R (18.83%), and HRE (12.55%). The largest age group was 45-54 years old (38%). The dominant gender was male (56.49%). The most treatment history category was relapsed patients (48%) and there were more patients with comorbidity (57%).Conclusion: The highest incidence rate of resistance was rifampicin and the most common resistance pattern was HR. Most of the patients were of working age, male, relapse patients, and had comorbidities. An appropriate TB therapy treatment plays an important role in preventing resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.